Dan Hecht, General Manager for P&G Pharmaceuticals, North America, said, "Because we're confident in the clinically proven fracture efficacy of Actonel, we're willing to stand behind our product with this unique fracture reimbursement program."
"The Alliance for Better Bone Health and Health Alliance care deeply about the medical outcomes their patients get as a result of taking products like Actonel," said Brent Ragans, Vice President, General Therapeutics, for sanofi-aventis. "We're very pleased to be working with the Health Alliance."
Osteoporosis is a silent disease that affects millions of postmenopausal women, making their bones weak and more likely to fracture over time. In fact, in the U.S. today, 8 million women are estimated to already have osteoporosis, and almost 27 million more are estimated to have low bone mass, placing them at increased risk for fracture. Each year the incidence of osteoporosis-related fractures is greater than the incidence of heart attacks, strokes, and breast cancer combined. The good news is that there are prescription medications available that effectively reduce both vertebral and nonvertebral fracture risk.
About Actonel (risedronate sodium) Tablets
Actonel is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine
|SOURCE Health Alliance Medical Plans, Inc.|
Copyright©2009 PR Newswire.
All rights reserved